Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vaidyane Ayurved Laboratories has a Cash Ratio of 2.08. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Vaidyane Ayurved Laboratories's Cash Ratio or its related term are showing as below:
NSE:MADHAVBAUG'
s Cash Ratio Range Over the Past 10 Years
Min: 0.05 Med: 1.28 Max: 2.08
Current: 2.08
During the past 8 years, Vaidyane Ayurved Laboratories's highest Cash Ratio was 2.08. The lowest was 0.05. And the median was 1.28.
NSE:MADHAVBAUG's Cash Ratio is ranked better than 78.88% of 966
companies
in the Drug Manufacturers industry
Industry Median: 0.57
vs NSE:MADHAVBAUG: 2.08
Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Vaidyane Ayurved Laboratories Cash Ratio Related Terms
Vaidyane Ayurved Laboratories Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vaidyane Ayurved Laboratories's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaidyane Ayurved Laboratories Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vaidyane Ayurved Laboratories's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Vaidyane Ayurved Laboratories's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) has a Cash Ratio of 2.08 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Vaidyane Ayurved Laboratories and its competitors. This is 63% above median its historical median of 1.28. Over the past decade, Vaidyane Ayurved Laboratories' Cash Ratio has ranged from 0.05 to 2.08. According to the industry distribution chart, Vaidyane Ayurved Laboratories ranks #204 out of 966 companies in the Drug Manufacturers industry, placing it in the top 21.1%.
Is Vaidyane Ayurved Laboratories' Cash Ratio too high?
Vaidyane Ayurved Laboratories' current Cash Ratio of 2.08 is 63% above median its 10-year median of 1.28. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 2.08. The Drug Manufacturers industry median Cash Ratio is 0.57. Vaidyane Ayurved Laboratories' value of 2.08 is 264.9% above this industry median. Based on the distribution chart, Vaidyane Ayurved Laboratories ranks #204 out of 966 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vaidyane Ayurved Laboratories has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vaidyane Ayurved Laboratories' Cash Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vaidyane Ayurved Laboratories ranks #204 out of 966 companies for Cash Ratio. This places Vaidyane Ayurved Laboratories in the top 21% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.57. Vaidyane Ayurved Laboratories' value of 2.08 is 264.9% above this benchmark. Historically, Vaidyane Ayurved Laboratories' own Cash Ratio has ranged from 0.05 to 2.08 over the past decade. While the company's 10-year median is 1.28 vs. the industry median of 0.57, Vaidyane Ayurved Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.57, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vaidyane Ayurved Laboratories's current Cash Ratio of 2.08 is 264.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Vaidyane Ayurved Laboratories and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vaidyane Ayurved Laboratories's current Cash Ratio is 2.08, which is 63% above median its own 10-year median of 1.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaidyane Ayurved Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) is currently considered Possible Value Trap. The stock's GF Value™ is ₹221.32, compared to a current price of ₹155.90 — trading 29.6% below its estimated fair value. The current Cash Ratio is 2.08, which is 63% above median its 10-year median of 1.28 and 264.9% above the Drug Manufacturers industry median of 0.57. Vaidyane Ayurved Laboratories' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG), the current Cash Ratio is 2.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) Overvalued in 2026?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories stock appears to be undervalued.
The current stock price of ₹155.90 is trading 29.6% below its estimated GF Value™ of ₹221.32.
GuruFocus considers Vaidyane Ayurved Laboratories to be Possible Value Trap.
Key valuation signals for NSE:MADHAVBAUG:
Cash Ratio: 2.08 (63% above median its 10-year median of 1.28)
GF Value™: ₹221.32 vs. price of ₹155.90 (29.6% below fair value)
Industry Position: 264.9% above the Drug Manufacturers median (#204 of 966)
No single metric tells the full story. See the NSE:MADHAVBAUG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vaidya Sane Ayurved Laboratories Ltd is a medical service institution. The company engaged in research and development in Ayurvedic Medicines and the sale of Ayurvedic medicines & products through its various franchises and own clinics. The Company is also engaged in providing Ayurved medical professional services across its various clinics, including panchkarma and other Ayurvedic treatments through the running of an Ayurvedic Hospital. The company mainly offers treatment for health disease reversal, diabetes reversal, BP management, obesity management, and knee pain relief. The company's business is divided into three segments, i.e., Hospital Activity, Sale of Product, and Common. It derives maximum revenue from the sale of Products.
73GF Score
Get the complete analysis for NSE:MADHAVBAUG
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MADHAVBAUG has been successfully added to your 
